Literature DB >> 21109747

Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro.

Naruo Shoji1, Kazuhito Asano, Atsuko Furuta, Kojiro Hirano, Harumi Suzaki.   

Abstract

BACKGROUND: Thymus- and activation-regulated chemokine (TARC) and macrophage-derived chemokine (MDC) are accepted to be important molecules in the development and maintenance of allergic diseases. Although several types of histamine H(1) receptor antagonist (antihistamine) have been developed and used for the treatment of allergic diseases, the influence of antihistamines on TARC and MDC production is not well understood.
OBJECTIVE: The present study was undertaken to examine the influence of antihistamines on TARC and MDC production from CD14+ cells after antigenic stimulation in vitro.
METHODS: CD14+ cells prepared from patients with pollinosis to Japanese cedar pollen were stimulated with specific allergen extracted from Japanese cedar pollen (Cry j 1) in the presence of azelastine (AZE), ketotifen (KET), fexofenadine (FEX) and oxatomide (OXA) for 6 days. TARC and MDC levels in culture supernatants were examined by ELISA. We also examined the influence of FEX on TARC and MDC mRNA expression, phosphorylation of mitogen-activated protein kinases (MAPKs) and transcription factor activation in CD14+ cells after Cry j 1 stimulation.
RESULTS: FEX at 250 ng/ml, which is almost equal to therapeutic blood levels, caused a significant inhibition of TARC and MDC production.However, AZE, OXA and KET required higher concentrations than their therapeutic blood levels to suppress production of these factors. FEX at 250 ng/ml also suppressed NF-κB activation, phosphorylation of p38 MAPK and extracellular signal-regulated kinases 1 and 2 and expression of mRNA for TARC and MDC.
CONCLUSIONS: These results suggest that antihistamines, especially FEX, suppress CC chemokine production from CD14+ cells through interference with antigen-mediated signaling and result in favorable modification of allergic disease states or conditions.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21109747     DOI: 10.1159/000318720

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  4 in total

1.  Tiotropium bromide inhibits TGF-β-induced MMP production from lung fibroblasts by interfering with Smad and MAPK pathways in vitro.

Authors:  Kazuhito Asano; Yusuke Shikama; Naruo Shoji; Kojiro Hirano; Harumi Suzaki; Hiroaki Nakajima
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-09-07

2.  Fucoidan inhibits CCL22 production through NF-κB pathway in M2 macrophages: a potential therapeutic strategy for cancer.

Authors:  Jia Sun; Jintang Sun; Bingfeng Song; Lin Zhang; Qianqian Shao; Yanguo Liu; Daoying Yuan; Yun Zhang; Xun Qu
Journal:  Sci Rep       Date:  2016-10-24       Impact factor: 4.379

3.  Inulae Flos and Its Compounds Inhibit TNF-α- and IFN-γ-Induced Chemokine Production in HaCaT Human Keratinocytes.

Authors:  Jung-Hoon Kim; Hye-Sun Lim; Hyekyung Ha; Chang-Seob Seo; Hyeun-Kyoo Shin
Journal:  Evid Based Complement Alternat Med       Date:  2012-08-07       Impact factor: 2.629

4.  Suppression of osteopontin functions by levocetirizine, a histamine H1 receptor antagonist, in vitro.

Authors:  Toshimitsu Komatsuzaki; Isao Suzaki; Kojiro Hirano; Ken-Ichi Kanai; Kazuhito Asano; Harumi Suzaki
Journal:  Biomed Res Int       Date:  2013-12-30       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.